1
|
Surh LC, Lesko LJ, Hobbs S, Gutman S, Minasian LM, Pasqua OED, Austin MJF, Lu K. Fit-for-purpose pharmacogenomic biomarkers in drug development: a project team case study with ‘what-ifs’. Pharmacogenomics 2009; 10:137-47. [DOI: 10.2217/14622416.10.1.137] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
Abstract
Over the past four years, the annual US FDA–DIA pharmacogenomic workshops have brought together attendees with wide-ranging expertise spanning industry, regulatory authorities and academia. This special report summarizes a breakout session using a novel, interactive case format as a way to engage participants, raise awareness and share diverse learnings via ‘real life’ decisions that project teams might face in developing a new medicine. This case was situated just prior to approval by a Regulatory Authority as a project team is finalizing a new medicine label. To effectively integrate new biomarkers such as pharmacogenomics into developing new medicines, this session highlighted the importance in considering medical practice implications as relevant (or not) to information or actions by a prescriber; progressing validation beyond assay to clinical; and fitting pharmacogenomics into context with other evidence often built over decades during a drug’s development. All converge onto a label that must communicate evidence–based use of a new medicine that is effective and safe.
Collapse
Affiliation(s)
- Linda C Surh
- CEDD, Global Regulatory Affairs, Neurology & Pharmacogenetics, GlaxoSmithKline, Greenford Road, Greenford, Middlesex, UB6 OHE, UK
| | | | - Stuart Hobbs
- Strategic Product Labelling, GlaxoSmithKline, USA
| | | | | | | | | | - Kan Lu
- Strategic Product Labelling, GlaxoSmithKline, USA
| |
Collapse
|
2
|
Higher incidence and serum levels of minor cardiac biomarker elevation in sirolimus-eluting stent (Cypher) than bare metal stent implantations. Coron Artery Dis 2008; 19:63-9. [DOI: 10.1097/mca.0b013e3282f2f189] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
3
|
Storti S, Prontera C, Parri MS, Iervasi A, Vittorini S, Emdin M, Zucchelli GC, Longombardo G, Migliorini P, Clerico A. Evaluation of the analytical performance of the advanced method for cardiac troponin I for the AxSYM platform: comparison with the old method and the Access system. Clin Chem Lab Med 2006; 44:1022-9. [PMID: 16879072 DOI: 10.1515/cclm.2006.175] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
AbstractClin Chem Lab Med 2006;44:1022–9.
Collapse
Affiliation(s)
- Simona Storti
- CNR Institute of Clinical Physiology, University of Pisa, Pisa, Italy
| | | | | | | | | | | | | | | | | | | |
Collapse
|